295 related articles for article (PubMed ID: 17674545)
1. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
Raccah E; Merimsky O; Kuten A; Apter S; Catane R
Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
3. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
6. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
[TBL] [Abstract][Full Text] [Related]
8. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
[TBL] [Abstract][Full Text] [Related]
9. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
10. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
[TBL] [Abstract][Full Text] [Related]
11. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
Gelibter A; Milella M; Ceribelli A; Zeuli M; Ferraresi V; Vecchione A; Cognetti F
Anticancer Res; 2004; 24(5B):3147-51. PubMed ID: 15510603
[TBL] [Abstract][Full Text] [Related]
12. Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate.
Chiang KC; Chen TW; Yeh CN; Liu FY; Lee HL; Jan YY
World J Gastroenterol; 2006 Apr; 12(13):2060-4. PubMed ID: 16610057
[TBL] [Abstract][Full Text] [Related]
13. Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.
Kasper B; Kallinowski B; Herrmann T; Lehnert T; Mechtersheimer G; Geer T; Ho AD; Egerer G
Dig Dis; 2006; 24(1-2):207-11. PubMed ID: 16699280
[TBL] [Abstract][Full Text] [Related]
14. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
15. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
[TBL] [Abstract][Full Text] [Related]
16. New strategies for treating GIST when imatinib fails.
Boyar MS; Taub RN
Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
[TBL] [Abstract][Full Text] [Related]
17. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
18. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
[TBL] [Abstract][Full Text] [Related]
20. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
